Haoyuan Chemexpress reports nine-month revenue growth of 28.52%
Regulatory / securities filing · 皓元医药 / 巨潮资讯 CNinfo
Source published: · Event / reporting date: 2026-09-30
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Haoyuan Chemexpress reported consolidated revenue of RMB2.646 billion, up 28.52%, and attributable net income of RMB308.8 million for the nine months ended September 30, 2026. Attributable net income rose 30.49%. Consolidated revenue combines multiple businesses rather than isolating CDMO service revenue. The quarterly filing is unaudited and covers the year-to-date period.
Why it may matter
Growth at the integrated platform offers an industry reference point, but comparisons still require separating research products from CDMO services.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections